XML 30 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Operations (USD $)
 12 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Revenue:      
Revenue from licensing agreements and grants $ 557,880 $ 927,772 $ 608,011
Revenue from product sales 662,790 499,200 384,859
Total revenue 1,220,670 1,426,972 992,870
Cost of product sales 214,811 168,424 261,443
Gross profit 1,005,859 1,258,548 731,427
Operating expenses:      
Research and development 19,937,764 21,019,301 19,929,592
Selling, general and administrative 8,202,375 9,376,774 9,530,421
Wind-down expenses 287,122 221,991 649,608
Impairment of intangible asset 654,961    
Total operating expenses 29,082,222 30,618,066 30,109,621
Operating loss (28,076,363) (29,359,518) (29,378,194)
Other income (expense):      
Realized gain on sale of marketable securities 83,750   406,910
Change in fair value of warrant liability 6,612,092 3,005,040 1,898,603
Interest income 13,942 26,728 67,345
Interest expense (71,363) (93,382) (110,807)
Qualifying therapeutic discovery project grant   977,917  
Other income (expense), net 109,404 199,664 89,732
Total other income (expense), net 6,747,825 4,115,967 2,351,783
Net loss $ (21,328,536) $ (25,243,551) $ (27,026,411)
Basic and diluted net loss per share $ (1.50) $ (2.05) $ (2.55)
Shares used to compute basic and diluted loss per share 14,187,885 12,330,299 10,604,596